2021年3月8日 · Tumor necrosis factor alpha (TNF-α) was initially recognized as a factor that causes the necrosis of tumors, but it has been recently identified to have additional important functions as a pathological component of autoimmune diseases.

2024年10月24日 · Members of the TNF superfamily (TNFSF) of ligands and their receptors have emerged as promising targets in the treatment of autoimmune diseases and cancer, with several biologics gaining FDA...

2022年11月15日 · Tumour necrosis factor (TNF) is a central cytokine in inflammatory reactions, and biologics that neutralize TNF are among the most successful drugs for the treatment of chronic inflammatory...

Tumor necrosis factor-alpha (TNF-α) is a pleiotropic immune cytokine belonging to the TNF superfamily of receptor ligands. It is involved in several homeostatic and inflammatory processes, and plays a major role in autoimmune and inflammatory diseases (1–3).

2023年10月1日 · Here we summarize the central role of TNF-α in immune disorders and how anti-TNF-based immunotherapies changed the therapeutic landscape, albeit with important limitations related to side effects, tolerance, and resistance to therapies.

Although initially described as an anti-tumor mediator, tumor necrosis factor-alpha (TNF) is generally considered as the master pro-inflammatory cytokine. It plays a crucial role in the pathogenesis of inflammatory diseases, such as rheumatoid ...

2021年3月8日 · In this review, we briefly introduce the impact of TNF-α signaling on autoimmune diseases and its inhibitors, which are used as therapeutic agents against autoimmune diseases.

The first anti-tumour necrosis factor (TNF) monoclonal antibody, infliximab (Remicade), celebrated its 25th anniversary of FDA approval in 2023. Inhibitors of TNF have since proved clinically efficacious at reducing inflammation associated with several autoimmune diseases, including rheumatoid arthr …

Tumor necrosis factor alpha (TNF-α) was initially recognized as a factor that causes the necrosis of tumors, but it has been recently identified to have additional important functions as a pathological component of autoimmune diseases.

Potential LCV causes include autoimmune diseases (i.e., RA, SLE, Sjogren, and Henoch–Schönlein purpura), infection, and drug-mediated immune reactions, especially TNF-α inhibitors. Some authors have suggested that host antibodies developed against anti-TNF-α agents may cause an immune-complex-mediated hypersensitivity reaction [ 79 ].